source
- Novartis drops mid-stage radioligand therapy 177Lu-NeoB after weak early dataNovartis has discontinued its mid-stage radioligand therapy 177Lu-NeoB, which was being tested for breast cancer and other solid tumors. The company said early clinical data did not show enough ef…
- Novartis beats sales expectations as Q2 revenue rises to $14.4B, eyes upcoming study readoutsNovartis reported a modest rise in second‑quarter sales, lifting its share price after the company posted a 1% increase in net sales to $14.4 billion, surpassing analyst forecasts for a decline. A…